[1]Macaron C, Hanouneh I A, Zein N N. Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology, 2015, 52(6):2240-2240. [2]Yoon Y I, Kim K H, Kang S H, et al. Purelaparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A propensity score matched analysis. Ann Surg, 2017, 265(5):856-863. [3]Ally A, Balasundaram M, Carlsen R, et al. Comprehensive andintegrative genomic characterization of hepatocellular carcinoma. Cell, 2017, 169(7):1327-1341. [4]Gulvady A C, Dubois F, Deakin N O, et al. Hic-5expression is a major indicator of cancer cell morphology, migration and plasticity in three-dimensional matrices. Mol Bio Cell, 2018, 29(13):1704-1717. [5]Li J, Ding Y, Li A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J Surg Oncol, 2016, 14(1):297-301. [6]罗程, 陈琪, 方程, 等. Hic-5基因在胆管纤维化中的表达. 实用医学杂志, 2018, 34(20):51-55. [7]Tao R, Fan X, Yu H, et al. MicroRNA-29b-3p prevents Schistosoma Japonicum‐induced liver fibrosis by targeting COL1A1 and COL3A1. J Cell Biochem, 2018, 8(1):102-110. [8]Pirisi M, Leutner M, Pinato D J, et al. Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med, 2010, 134(12):1818-1822. [9]张杰, 段伯焕, 朱功兵. 肝细胞癌患者外科手术根治术后生存分析. 实用肝脏病杂志, 2017, 20(1):93-96. [10]Sheta R, Wang Z Q, Bachvarova M, et al. Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. Oncotarget, 2017, 8(47):82506-82530. [11]Lei X F, Fu W, Kim-Kaneyama J R, et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol, 2016, 64(1):110-117. [12]张金莲, 蔡兆根, 吴琼, 等. 肝细胞癌患者血清和肝组织microRNAlet-7水平及其与临床预后的关系. 实用肝脏病杂志, 2018, 21(3):119-122. [13]Schleit J, Bailey S S, Tran T, et al. Molecularoutcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proα1(I) chains of type I procollagen. Hum Mutat, 2015, 36(7):728-739. [14]Zhang Z, Wang Y, Zhang J, et al. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep, 2018, 17(4):1-6. [15]Jolly L A, Novitskiy S V, Owens P, et al. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res, 2016, 76(7):1804-1813. [16]Nick H, Andrew M. Extracellular matrix-induced Hic-5 expression in glomerular mesangial cells leads to a prosclerotic phenotype independent of TGF-β. Faseb J, 2015, 29(12):4956-4967. [17]Zhang S, Gong Y, Xiao J, et al. A COL1A1promoter-controlled expression of TGF-β soluble receptor inhibits hepatic fibrosis without triggering autoimmune responses. Dig Dis Sci, 2018, 63(10):2662-2672. [18]Goreczny G J, Forsythe I J, Turner C E. Hic-5regulates fibrillar adhesion formation to control tumor extracellular matrix remodeling through interaction with tensinl. Oncogene, 2018, 37(13):1699-1713. [19]Shen L, Yang M, Lin Q, et al. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep, 2016, 36(2):877-885. [20]Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 317–370. |